The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 9, 2012, Pages 1054-1063

  Navaneethan, U ^a   Choudhary, M ^a   Venkatesh, P G K ^a   Lashner, B A ^a   Remzi, F H ^a   Shen, B ^a   Kiran, R P ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CHRONIC DRUG ADMINISTRATION; COLON CARCINOMA; COLON DYSPLASIA; COLON RESECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GASTROINTESTINAL DYSPLASIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; AGED; CHOLANGITIS, SCLEROSING; COHORT STUDIES; COLECTOMY; COLITIS, ULCERATIVE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; LIVER TRANSPLANTATION; MALE; MESALAMINE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84875759561     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05067.x     Document Type: Article

References (43)

1. Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1598-619.
2. Olsson R, Danielsson A, Jarnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100: 1319-23.
3. Broome? U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006; 26: 31-40.
4. Loftus EV, Sandborn WJ, Lindor KD, et al. Interactions between chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis 1997; 3: 288-302.
5. Faubion WA, Loftus EV, Sandborn WJ, et al. Pediatric ''PSC-IBD'': a descriptive report of associated inflammatory bowel disease among pediatric patients with PSC. J Pediatr Gastroenterol Nutr 2001; 33: 296-300.
6. Loftus EV, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-6.
7. Heuschen U, Hinz U, Allemeyer E, et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001; 120: 841-7.
8. Joo M, Abreu-e-Lima P, Farraye F, et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol 2009; 33: 854-62.
9. Marelli L, Xirouchakis E, Kalambokis G, Cholongitas E, Hamilton MI, Burroughs AK. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 2011; 60: 1224-8.
10. Navaneethan U, Venkatesh PG, Mukewar S, et al. Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2012 [Epub ahead of print].
11. Befeler AS, Lissoos TW, Schiano TD, et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 1998; 65: 393-6.
12. Gavaler JS, Delemos B, Belle SH, et al. Ulcerative colitis disease activity as subjectively assessed by patient completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis. Dig Dis Sci 1991; 36: 321-8.
13. Miki C, Harrison JD, Gunson BK, Buckels JA, McMaster P, Mayer AD. Inflammatory bowel disease in primary sclerosing cholangitis: an analysis of patients undergoing liver transplantation. Br J Surg 1995; 82: 1114-7.
14. Papatheodoridis GV, Hamilton M, Mistry PK, Davidson B, Rolles K, Burroughs AK. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998; 43: 639-44.
15. Shaked A, Colonna JO, Goldstein L, Busuttil RW. The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation. Ann Surg 1992; 215: 598-603.
16. Graziadei IW, Wiesner RH, Marotta PJ, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999; 30: 1121-7.
17. Saldeen K, Friman S, Olausson M, Olsson R. Follow-up after liver transplantation for primary sclerosing cholangitis: effects on survival, quality of life, and colitis. Scand J Gastroenterol 1999; 34: 535-40.
18. van der Vrie V, de Man RA, van Buuren HR, Schouten WR, Tilanus HW, Metselaar HJ. Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2003; 15: 657-63.
19. Ho GT, Seddon AJ, Therapondos G, Satsangi J, Hayes PC. The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation. Eur J Gastroenterol Hepatol 2005; 17: 1379-85.
20. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 31-9.
21. Kim WR, Poterucha JJ, Wiesner RH, et al. The relative role of the Child- Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 1999; 29: 1643-8.
22. Jorgensen KK, Grzyb K, Lundin KE, et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: Clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2012; 18: 536-45.
23. Kitis G, Wright HI, Abu-Elmagd K, et al. The course of inflammatory bowel disease under FK 506 immunosuppression after liver transplantation for primary sclerosing cholangitis. Hepatology 1992; 16 (Suppl.): 191A.
24. Fabry TL, Klion FM, Post JA, et al. Outcome of liver transplantation (OLTX) for primary sclerosing cholangitis (PSC) and the effect of immunosuppression on the course of inflammatory bowel disease. Hepatology 1993; 18(Suppl.): 69A.
25. Marotta PJ, Graziadei IW, Wiesner RH, et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis receiving liver transplantation. Hepatology 1997; 26 (Suppl.): 237A.
26. Moncrief KJ, Savu A, Ma MM, Bain VG, Wong WW, Tandon P. The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation- A single-centre experience. Can J Gastroenterol 2010; 24: 40-6.
27. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345-53.
28. Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 2011; 106: 731-6.
29. Feagan BG, McDonald JWD, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994; 330: 1846-51.
30. Jewell DP, Lennard-Jones JE, the Cyclosporin Study Group of Great Britain and Ireland. Oral cyclosporin for chronic active Crohn's disease: a multicentre controlled trial. Eur J Gastroenterol Hepatol 1994; 6: 499-505.
31. Stange EF, Modigliani R, Pena AS, et al. European trial of cyclosporine in chronic active Crohn's disease: a 12- month study. Gastroenterology 1995; 109: 774-82.
32. Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334: 841-8.
33. Cholongitas E, Shusang V, Papatheodoridis GV, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008; 14: 138-43.
34. Broome U, Lofberg R, Veress B, et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-8.
35. Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997; 41: 522-5.
36. Claessen MMH, Vleggaar FP, Tytgat KMAJ, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2008; 50: 158-64.
37. Brentnall TA, Haggitt RC, Rabinovitch PS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996; 110: 331-8.
38. Bleday R, Lee E, Jessurum J, et al. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum 1993; 36: 908-12.
39. Knechtle SJ, D'Alessandro AM, Harms BA, et al. Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation. Surgery 1995; 118: 615-20.
40. Narumi S, Roberts JP, Emond JC, et al. Liver transplantation for sclerosing cholangitis. Hepatology 1995; 22: 451-7.
41. Navaneethan U, Kochhar G, Venkatesh PG, et al. Duration and severity of primary sclerosing cholangitis is not associated with the risk of neoplastic changes in the colon in patients with ulcerative colitis. Gastrointest Endosc 2012 [Epub ahead of print].
42. Alabraba E, Nightingale P, Gunson B, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009; 15: 330-40.
43. Vera A, Moledina S, Gunson B, et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002; 360: 1943-4.